Biocompatibles
This article was originally published in The Gray Sheet
Executive Summary
British firm will return roughly $143.6 mil. ($1.01 per ordinary share) to shareholders following the March 18 acquisition of its stent manufacturing facility by Abbott Labs (1"The Gray Sheet" March 25, 2002, p. 3)...